Humacyte: Cash Burn And A Glacial Launch Overshadow VAC Progress
2025-08-12 13:20:47 ET
Humacyte Overview
Humacyte stock ( HUMA ) plummeted 30% following its second-quarter earnings report . My last report on HUMA followed its first-quarter earnings report. SYMVESS, which is marketed for the treatment of extremity vascular trauma, was just launched earlier this year. Ironically, Humacyte was making moves to reduce costs, including slashing its workforce. I have expressed caution in the past regarding Humacyte’s niche market opportunity and the challenges in larger indications, such as hemodialysis access and coronary arterial bypass grafts (CABG). These operational issues, alongside cash burn and a limited cash runway, prompted my Sell rating in HUMA....
Read the full article on Seeking Alpha
For further details see:
Humacyte: Cash Burn And A Glacial Launch Overshadow VAC Progress
NASDAQ: HUMAW
HUMAW Trading
10.37% G/L:
$0.1181 Last:
1,550 Volume:
$0.1087 Open:
